SEOUL, South Korea, Nov. 30, 2005 (PRIMEZONE) -- Meridian Co., Ltd. (Meridian) (OTCBB:MRDAF) today announced that it has received a positive endorsement of its Digital Pulse Analyzer product from Dr. Saul Isserow. The study performed by Dr. Isserow was undertaken completely independently without any input or influence by any Meridian associate or principal.
Dr. Isserow is a Royal College Certified Cardiologist, a staff cardiologist at University of British Columbia Hospital and Vancouver General Hospital and holds the positions of Director of the Vancouver General Hospital Centre for Cardiac Rehabilitation and Risk Factor Management and Associate Director of Cardiology at the University of British Columbia Hospital.
The study was conducted in conjunction with an existing program to measure the effects of training on semi-professional tri-athletes, in cooperation with the Kinesiology Department of the University of British Columbia. Parameters of the study included analysis prior to and following competition in a triathlon.
Conclusions of the study relating particularly to the Digital Pulse Analyzer include:
1) The machine is noninvasive and safe
2) The machine is accurate at measuring the parameters it is designed
to measure
3) The measurement of heart rate variability, a marker for
cardiovascular health, is accurate.
About Digital Pulse Analyzer (DPA)
The DPA accurately measures the elasticity of small and large arteries and provides health care practitioners with critical information regarding arterial aging. This FDA-approved device is inexpensive, non-invasive and can provide results in minutes. Accumulating evidence suggests that abnormalities in the pulsatile characteristics of arteries occur early in the disease process associated with increased cardiovascular risk, and can be favorably modified by therapeutic interventions.
Meridian feels that use of the DPA can help caregivers reduce cardiovascular disease in their patient populations through early detection and prevention and ultimately assist to decrease the associated financial costs placed on the healthcare industry. Cardiovascular disease is the number one killer in the United States with an estimated economic cost of approximately $298 billion.
Meridian is committed to the ongoing global research and advancement of integrative medical products that contribute to the better health of humanity.
On Behalf of the Board of Directors, Hyeon Seong Myeong President
This press release may contain certain forward-looking information and statements concerning the company's operations, performance and financial condition. These statements are based upon a number of uncertainties and contingencies, many of which are beyond the control of the company. Actual results may differ materially from those expressed or implied by such forward-looking statements. This document is not intended to be and is not an advertisement for any securities of the company.
HTML: http://newsroom.eworldwire.com/wr/113005/13233.htm PDF: http://newsroom.eworldwire.com/pdf/113005/13233.pdf ONLINE NEWSROOM: http://newsroom.eworldwire.com/307280.htm NEWSROOM RSS FEED: http://newsroom.eworldwire.com/xml/newsrooms/307280.xml LOGO: http://newsroom.eworldwire.com/307280.htm